3.8 Article

(-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells

Journal

CANCER DETECTION AND PREVENTION
Volume 31, Issue 6, Pages 499-504

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cdp.2007.10.018

Keywords

green tea; chemoprevention; estrogen receptor signaling; pS2; endocrine therapy; tamoxifen; ICI 182,780; MDA-MB-231; RT-PCR; MTT assay

Categories

Ask authors/readers for more resources

Background: (-)-Epigallocatechin-3-gallate (EGCG) is the most active catechin present in green tea, demonstrated to have chemopreventive action and to kill cancer cells selectively. As a previous study found that catechins could compete with 17-beta-estradiol for binding to estrogen receptor alpha (ER alpha), we asked whether EGCG could regulate ER alpha action. Methods: We used MCF-7, a breast carcinoma cell line having a high level of ERa expression. The cells were treated with various EGCG concentrations and cell viability was evaluated by MTT assay. ERa and pS2 expression were analyzed by RT-PCR after RNA extraction. To better define EGCG action in relation to ER alpha, we studied EGCG cytotoxicity on MCF-7 resistant to tamoxifen (MCF-7tam), MCF-7 treated with 10(-7) M ICI 182,780 for 8 days and on MDA-MB-231, a cell line that lacked ERa by flow cytometry (FCM). Results: Both ERa and pS2 mRNA were expressed in samples treated with low EGCG concentration (30 mu g/ml). At this concentration, no cell change was detectable. In contrast, pS2 expression was lost in samples treated with 100 mu g/ml EGCG for 24 h, indicating ERa alteration. EGCG cytotoxicity was lower when ERa was not present (MDA-MB-231) or inactivated (by tamoxifen or ICI 182,780). Conclusions: Functionally active ER(x may have a role in EGCG cytotoxicity, increasing the sensitivity to the drug. As higher EGCG concentrations also killed cells resistant to tamoxifen or treated by 10-7 M ICI 182,780, EGCG ought to be better :investigated in breast carcinoma cells treated with drugs targeted to steroid receptors, as a potential complement of therapy. (C) 2007 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available